Navigation Links
WellPoint to Reduce Operating Expenses for Continued Long-Term Success
Date:1/16/2009

ttp://www.wellpoint.com/" target="_new">www.wellpoint.com.

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995

The Company and its representatives may from time to time make written and oral forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA), including statements in this report, in presentations, press releases, filings with the Securities and Exchange Commission, or SEC, and reports to shareholders and in meetings with analysts and investors. The projections referenced in this report are forward-looking and they are intended to be covered by the safe harbor for "forward-looking statements" provided by PSLRA. Words such as "expect(s)", "feel(s)", "believe(s)", "will", "may", "anticipate(s)", "intend", "estimate", "project" and similar expressions are intended to identify forward-looking statements, which generally are not historical in nature. These statements include, but are not limited to, financial projections and estimates and their underlying assumptions; statements regarding plans, objectives and expectations with respect to future operations, products and services; and statements regarding future performance. Such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond our control, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include those discussed and identified in our public filings with the SEC; and, risks and uncertainties regarding estimated severance costs, including changes in the actual number as compared to the assumed number for the Company's tax rate, amount of severed employees and amount payable to severed employees. Readers are cautioned not to place undue reliance on these forward-looking statements th
'/>"/>

SOURCE WellPoint, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. WellPoint Announces Appearances at Upcoming Conferences
2. WellPoint and M-Plan Enter Into Endorsement Agreement as M-Plan Announces Exit From the Commercial HMO Business in Indiana
3. WellPoint Announces Realignment of Core Businesses; Names New Executives
4. Wellpoint NextRx Receives TIPPS Certification from the HR Policy Association
5. WellPoint NextRx Receives National Leadership Award for Innovative Web Tool
6. WellPoint Reports Third Quarter 2007 Results
7. WellPoint Taps Zagat Survey to Help Consumers Rate Experiences with Their Doctors
8. WellPoint Provides Support and Resources to Most Vulnerable California Residents
9. WellPoint Announces Appointment of John Cannon III as Executive Vice President & General Counsel
10. WellPoint Highlights 2007 Accomplishments and Strong 2008 Outlook at Annual Investor Meeting
11. WellPoint Announces Appointment of John Langenus as President of Anthem National Accounts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2009)... ORLEANS, Dec. 6 Sickle cell disease, ... blood cells, is one of the most common ... the world, including more than 70,000 Americans.(1) Research ... the American Society of Hematology highlights intriguing studies ... presents for children with this blood disorder, evaluations ...
(Date:12/6/2009)... Dec. 6, 2009 A new study provides welcome ... as venous thromboembolism (VTE). , The condition is ... year, and occurs when an abnormal clot forms in ... pain and swelling. In some cases, the clot may ... the heart to the lungs, causing a potentially fatal ...
(Date:12/6/2009)... Volunteer organizations and members of the community, in cooperation with the ... create a holiday party. This year,s attendance is expected to soar ... , ... (PRWEB) December 6, 2009 -- ... Greater VA Healthcare System in West Los Angeles, will once again ...
(Date:12/5/2009)... a phase 1/2 clinical trial that it is ... newly diagnosed with multiple myeloma, a cancer of white ... Cancer Institute. , Partial responses or better were seen ... drug combination in the multi-center study, with 74 percent ... phase 2 population, reports Paul G. Richardson, MD, of ...
(Date:12/5/2009)... Cuts for a Cause ,, Why: ... other terminal illnesses affecting children. All proceeds from each hair ... Hospital. Guests will enjoy complimentary beverages and hors d,oeuvres, provided ... Falls Church for all guests. Hoa Lai, a DJ known ...
Breaking Medicine News(10 mins):Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 2Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 3Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 4Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 5Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 6Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 7Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 8Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 9Health News:New drug shows promise for those with clotting disorders: McMaster researcher 2Health News:17th Annual Event Honoring 5,000 + Veterans, Military Personnel to Include Real Life “Heroes” 2Health News:17th Annual Event Honoring 5,000 + Veterans, Military Personnel to Include Real Life “Heroes” 3Health News:Multiple myeloma patients experience high response rate with new 3-drug combination 2
... to Reduce Disparities in Meningococcal Vaccination; Increase Educational Efforts ... Dec. 2 The National Foundation for ... Protect.) Meningitis! coalition, composed of many of ... a Call to Action to improve adolescent meningococcal vaccination ...
... safe, research shows , , TUESDAY, Dec. 2 (HealthDay News) -- ... more prone to error than if they were speaking with ... new report finds. , "We think it is basically a ... sitting next to you who is experienced as a driver, ...
... Focus-- , , ... of breakthrough nanoscale platforms for molecular diagnostics, personalized ... of Gary Zweiger, Ph.D., as vice president of ... decade of strategic business development experience with leading ...
... Neuralstem Inc.,(NYSE Alternext US: CUR) announced today that ... University & Hospital of Taiwan, to,advance development of Neuralstem,s ... will focus on Amyotrophic Lateral Sclerosis (ALS,or Lou Gehrig,s ... , (Logo: ...
... Dec. 2 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical,Inc. ... CSKI ), a leading,fully integrated pharmaceutical ... China ("PRC"), announced today that Mr. Yu-bo,(Stanley) Hao ... will,also serve on the Company,s Board of Directors. ...
... MYL ) today,announced that it and its subsidiary, ... Novartis Pharmaceuticals Corp., Novartis,Corp. and Novartis International AG related ... Mylan,s Vice Chairman ... to have reached this agreement, which demonstrates our ability ...
Other Medicine News:Health News:NFID Expands Educational Efforts To Reach Racial, Ethnic Families About Dangers of Meningitis 2Health News:NFID Expands Educational Efforts To Reach Racial, Ethnic Families About Dangers of Meningitis 3Health News:NFID Expands Educational Efforts To Reach Racial, Ethnic Families About Dangers of Meningitis 4Health News:Car Cell Phone Use More Hazardous Than Chat With Passengers 2Health News:Car Cell Phone Use More Hazardous Than Chat With Passengers 3Health News:BioNanomatrix Appoints Gary Zweiger, Ph.D., as Vice President of Business Development 2Health News:BioNanomatrix Appoints Gary Zweiger, Ph.D., as Vice President of Business Development 3Health News:Neuralstem Collaborates with Hospital in Taiwan to Develop Additional ALS Stem Cell Clinical Trials 2Health News:China Sky One Medical, Inc. Appoints Yu-bo Hao as CFO 2Health News:China Sky One Medical, Inc. Appoints Yu-bo Hao as CFO 3Health News:Mylan Announces Settlement Agreement with Novartis Related to Femara(R) First- to-File Opportunity 2
(Date:12/4/2009)... Inc. (NYSE: HSP ), a leading global ... launch of its next-generation 50 mL and 100 mL ... now offers a complete size range (50 mL to ... The launch of the 50 mL and 100 mL ...
(Date:12/4/2009)... 4 OrthoAccel Technologies, Inc., developers of the ... device to enhance orthodontics, announced the availability of ... PennWell Corporation , a leader in professional education ... The course focuses on patient views about orthodontic ...
(Date:12/4/2009)... AstraZeneca (NYSE: AZN ) today announced that ... once-daily SEROQUEL XR® (quetiapine fumarate) Extended Release Tablets as ... Depressive Disorder (MDD). SEROQUEL XR is the only medication ... both major depressive disorder as adjunctive therapy and acute ...
Breaking Medicine Technology:Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 2Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 3Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 4AcceleDent Science is Showcased in New Continuing Education Course Published by PennWell 2AcceleDent Science is Showcased in New Continuing Education Course Published by PennWell 3AcceleDent Science is Showcased in New Continuing Education Course Published by PennWell 4US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 2US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 3US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 4US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 5US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 6US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 7US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 8US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 9University of Toronto helps to barcode the worlds plants 9394 1University of Toronto helps to barcode the worlds plants 9394 2Study shows cancer vaccines led to long term survival for patients with metastatic melanoma 9391 1Study shows cancer vaccines led to long term survival for patients with metastatic melanoma 9391 2Gloomy Days Dim Cognitive Powers of the Depressed 52961 1Gloomy Days Dim Cognitive Powers of the Depressed 52961 2
... is recommended for separations of DNA fragments ... that are easy to handle, and remains ... minimizes the risk of cracking or breaking. ... (GQT) products with similar sieving properties, is ...
... Agarose-HR™ High Resolution - ... from 50 to 1000 ... for sizing PCR fragments, ... by restriction enzyme digestion, ...
The reading of agglutinations process in Diana Reader is by image treatment which allows great sensitivity....
... designed for medium to ... centers and reference laboratories ... antibody screening. It will ... functions including blood group ...
Medicine Products: